Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey N Siegel

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Protocols in Immunology|April 25, 2008
Preparation and analysis of phosphorylated proteinsJeffrey N Siegel
Current Protocols in Immunology|April 25, 2008
Antiphosphotyrosine blottingJeffrey N Siegel
Arthritis and Rheumatism|June 4, 2005
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favorJeffrey N Siegel, Bo-Guang Zhen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2004
Tuberculosis cases associated with infliximab and etanerceptKevin L Winthrop, Jeffrey N Siegel
JAMA|November 9, 2006
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritisSarah K Okada, Jeffrey N Siegel
Frontiers in Medicine|March 7, 2022
Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing ApplicationsAbena S Agyeman, Jeffrey N Siegel, Christopher Leptak
Annals of the Rheumatic Diseases|April 15, 2008
Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievableDavid T Felson, Bin Zhang, Jeffrey N Siegel
Current Opinion in Rheumatology|April 23, 2003
Infectious complications of biologic treatments of rheumatoid arthritisAparna K Mohan, Timothy R Coté, Jeffrey N Siegel, et al.
Arthritis and Rheumatism|October 4, 2005
Tuberculosis associated with therapy against tumor necrosis factor alphaKevin L Winthrop, Jeffrey N Siegel, John Jereb, et al.
Lancet (London, England)|September 21, 2002
Drug-induced systemic lupus erythematosus and TNF-alpha blockersAparna K Mohan, Evelyne T Edwards, Timothy R Coté, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Protocols in Immunology|April 25, 2008
Preparation and analysis of phosphorylated proteinsJeffrey N Siegel
Current Protocols in Immunology|April 25, 2008
Antiphosphotyrosine blottingJeffrey N Siegel
Arthritis and Rheumatism|June 4, 2005
Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favorJeffrey N Siegel, Bo-Guang Zhen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2004
Tuberculosis cases associated with infliximab and etanerceptKevin L Winthrop, Jeffrey N Siegel
JAMA|November 9, 2006
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritisSarah K Okada, Jeffrey N Siegel
Frontiers in Medicine|March 7, 2022
Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing ApplicationsAbena S Agyeman, Jeffrey N Siegel, Christopher Leptak
Annals of the Rheumatic Diseases|April 15, 2008
Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievableDavid T Felson, Bin Zhang, Jeffrey N Siegel
Current Opinion in Rheumatology|April 23, 2003
Infectious complications of biologic treatments of rheumatoid arthritisAparna K Mohan, Timothy R Coté, Jeffrey N Siegel, et al.
Arthritis and Rheumatism|October 4, 2005
Tuberculosis associated with therapy against tumor necrosis factor alphaKevin L Winthrop, Jeffrey N Siegel, John Jereb, et al.
Lancet (London, England)|September 21, 2002
Drug-induced systemic lupus erythematosus and TNF-alpha blockersAparna K Mohan, Evelyne T Edwards, Timothy R Coté, et al.
Pageof 2